- Current report filing (8-K)
April 22 2009 - 12:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 22, 2009
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-27354
|
|
65-0403311
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
30831 Huntwood Avenue, Hayward, CA
|
|
94544
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(510) 476-2000
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Item 8.01 Other Events.
On April 22, 2009, the Company distributed a letter to its employees discussing the Companys
recent accomplishments, its current business strategies and the expected principal drivers of its
future growth. The letter includes the Companys estimate of the market potential for its two lead
product candidates in its Branded Pharmaceutical Products division, which it has not previously
disclosed publicly. A copy of this letter is attached hereto as
Exhibit 99.1
and
incorporated by reference herein.
Statements included in the attached letter that do not relate to present or historical
conditions are forward-looking statements. Additional oral or written forward-looking statements
may be made by the Company from time to time. Such forward-looking statements involve risks and
uncertainties that could cause results or outcomes to differ materially from those expressed in the
forward-looking statements. Forward-looking statements may include statements relating to the
Companys plans, strategies, objectives, expectations and intentions. Words such as believes,
forecasts, intends, possible, estimates, anticipates, and plans and similar expressions
are intended to identify forward-looking statements. The Companys ability to predict results or
the effect of events on its operating results is inherently uncertain. Forward-looking statements
involve a number of risks, uncertainties and other factors that could cause actual results to
differ materially from those discussed in this letter. Such risks and uncertainties include the
effect of current economic conditions on the Companys industry, business, financial position,
results of operations and market value of its common stock, its ability to timely file periodic
reports required by the Securities Exchange Act of 1934, its ability to maintain an effective
system of internal control over financial reporting, its ability to sustain profitability and
positive cash flows, its ability to maintain sufficient capital to fund operations, any delays or
unanticipated expenses in connection with the construction of its Taiwan facility, its ability to
successfully develop and commercialize pharmaceutical products, the uncertainty of patent
litigation, consumer acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, the difficulty of predicting FDA filings and approvals,
inexperience in conducting clinical trials and submitting new drug applications, reliance on key
alliance agreements, the availability of raw materials, the regulatory environment, exposure to
product liability claims, fluctuations in operating results and other risks described in the
Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2008. You should not
place undue reliance on forward-looking statements. Such statements speak only as to the date on
which they are made, and the Company undertakes no obligation to update publicly or revise any
forward-looking statement, regardless of future developments or availability of new information.
In addition, significant changes and volatility in the current economic environment and in the
competitive landscape may make it increasingly difficult for the Company to predict its future
revenues and earnings. As a result, any estimates or guidance with respect to future revenue,
earnings, cash flow from operations, expenses or other financial metrics that the Company has
provided, including statements made in the attached letter, may be overtaken by future market
developments or may otherwise turn out to be inaccurate. Though the Company endeavors to give
reasonable estimates of future results at the time it provides such estimates, there is a
significant likelihood that such estimates, by their nature, will turn out to be incorrect.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is filed herewith.
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Letter to Employees dated April 22, 2009.
|
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 22, 2009
|
|
|
|
|
|
IMPAX LABORATORIES, INC
.
|
|
|
By:
|
/s/ Arthur A. Koch, Jr.
|
|
|
|
Name:
|
Arthur A. Koch, Jr.
|
|
|
|
Title:
|
Senior Vice President, Finance, and
Chief Financial Officer
|
|
2
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
99.1
|
|
Letter to Employees dated April 22, 2009.
|
3
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2023 to Jul 2024